- Home
- MGNX vs DLHC Comparison
MGNX vs DLHC Comparison
Compare MGNX & DLHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- DLHC
- Stock Information
- Founded
- MGNX 2000
- DLHC 1969
- Country
- MGNX United States
- DLHC United States
- Employees
- MGNX N/A
- DLHC N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- DLHC Business Services
- Sector
- MGNX Health Care
- DLHC Consumer Discretionary
- Exchange
- MGNX Nasdaq
- DLHC Nasdaq
- Market Cap
- MGNX 99.7M
- DLHC 80.6M
- IPO Year
- MGNX 2013
- DLHC N/A
- Fundamental
- Price
- MGNX $1.86
- DLHC $5.83
- Analyst Decision
- MGNX Hold
- DLHC
- Analyst Count
- MGNX 6
- DLHC 0
- Target Price
- MGNX $3.20
- DLHC N/A
- AVG Volume (30 Days)
- MGNX 726.3K
- DLHC 10.7K
- Earning Date
- MGNX 11-04-2025
- DLHC 12-03-2025
- Dividend Yield
- MGNX N/A
- DLHC N/A
- EPS Growth
- MGNX N/A
- DLHC 80.25
- EPS
- MGNX N/A
- DLHC 0.31
- Revenue
- MGNX $165,495,000.00
- DLHC $359,723,000.00
- Revenue This Year
- MGNX N/A
- DLHC N/A
- Revenue Next Year
- MGNX N/A
- DLHC N/A
- P/E Ratio
- MGNX N/A
- DLHC $18.54
- Revenue Growth
- MGNX 303.47
- DLHC N/A
- 52 Week Low
- MGNX $0.99
- DLHC $2.72
- 52 Week High
- MGNX $5.10
- DLHC $9.58
- Technical
- Relative Strength Index (RSI)
- MGNX 55.15
- DLHC 58.98
- Support Level
- MGNX $1.82
- DLHC $5.53
- Resistance Level
- MGNX $2.15
- DLHC $5.88
- Average True Range (ATR)
- MGNX 0.13
- DLHC 0.16
- MACD
- MGNX 0.01
- DLHC 0.03
- Stochastic Oscillator
- MGNX 49.15
- DLHC 70.21
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.